A meta-analysis of 1,552 patients found that dual-agonist incretin drugs (GIP/GLP-1 and GCGR/GLP-1) were 3-4 times more effective than single GLP-1 agonists at reducing liver fat in people with diabetes and fatty liver disease.
OR 35.31 vs. 8.23Dual GCGR/GLP-1 agonists showed a 35-fold odds of reducing liver fat content compared to placebo — over 4 times the effect of single GLP-1 agonists (OR 8.23) — in people with diabetes and fatty liver disease.
What the researchers found
This meta-analysis of 13 randomized controlled trials (1,552 patients) found that GLP-1 receptor agonists, dual GIP/GLP-1 receptor agonists, and GCGR/GLP-1 receptor agonists all significantly reversed liver fibrosis (OR 3.72, p<0.001) and reduced liver fat content (mean decrease of 18.9%, p<0.001) in people with type 2 diabetes and fatty liver disease. Critically, dual-agonist drugs outperformed single GLP-1 agonists: GIP/GLP-1 agonists (like tirzepatide) showed an OR of 28.90 and GCGR/GLP-1 agonists an OR of 35.31 for liver fat reduction, compared to 8.23 for single GLP-1 agonists alone.
Why it matters
Metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD) affects roughly 30% of the global population and is the fastest-growing cause of liver transplant. Until recently, there were no approved pharmacological treatments for liver fibrosis from fatty liver disease. This meta-analysis shows that incretin-based therapies — especially dual-agonist drugs — can both reduce liver fat and reverse fibrosis, potentially preventing progression to cirrhosis and liver failure. The superiority of dual agonists over single GLP-1 drugs is particularly significant for treatment selection.
The numbers in context
13 RCTs · n=1,552 · Fibrosis reversal OR 3.72 (p<0.001) · LFC reduction MD -18.9% (p<0.001) · GIP/GLP-1 OR 28.90 · GCGR/GLP-1 OR 35.31 · Single GLP-1 OR 8.23
How the study worked
Systematic search of PubMed, Web of Science, Scopus, and Cochrane databases for randomized controlled trials examining GLP-1 agonists, dual GIP/GLP-1 agonists, or GCGR/GLP-1 agonists in patients with both type 2 diabetes and MASLD. Outcomes included liver fibrosis reversal and liver fat content measured by MRI. Random-effects meta-analysis calculated mean differences and odds ratios with 95% confidence intervals across 13 studies.
Who was studied
1,552 individuals with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease across 13 randomized controlled trials
What this study cannot tell us
The included studies likely had varying definitions of MASLD/fibrosis, different drug doses and durations, and heterogeneous patient populations. The comparison between dual and single agonists may be confounded by differences in study populations and follow-up periods. Most included trials were designed primarily for diabetes outcomes, with liver endpoints as secondary. The meta-analysis compares drug classes broadly rather than head-to-head comparisons of specific medications.
How to read the evidence
This is a systematic review and meta-analysis of 13 randomized controlled trials — a high level of evidence. The results are statistically robust with consistent findings across drug classes. Limitations include potential heterogeneity between included studies and the indirect nature of the class comparisons.
When this study was published
Published in 2025, this meta-analysis captures the latest clinical trial data on incretin-based therapies for MASLD, including results from recent dual-agonist studies. It is highly relevant to current treatment decisions.
The bigger picture
Fatty liver disease has quietly become one of the world's most common chronic conditions, affecting nearly a third of the global population. The convergence of GLP-1-based obesity/diabetes drugs with liver disease treatment represents a potential game-changer — treating multiple metabolic conditions simultaneously. This meta-analysis adds to growing evidence that dual-agonist drugs (tirzepatide, survodutide) may be especially effective for liver disease, potentially establishing them as preferred treatments for the enormous population with overlapping diabetes and fatty liver disease.
Questions still open
- Are the liver benefits of dual-agonist drugs primarily driven by greater weight loss, or do they have direct hepatoprotective effects?
- How do these incretin-based therapies compare to resmetirom (the first FDA-approved drug specifically for liver fibrosis in NASH)?
- Do the liver fat and fibrosis improvements persist long-term, or do they reverse if the medications are discontinued?
Common questions
What is MASLD and why should diabetics care?
Are dual-agonist drugs better than single GLP-1 drugs for fatty liver?
Read the original research
Dual GIP/GLP1-RA, GCGR/GLP-1 RA and GLP1-RA for the Treatment of Metabolic Dysfunction-associated Steatotic Liver Disease with Type 2 Diabetes: A Systematic Review and Meta-analysis.
TouchREVIEWS in endocrinology, 21(2), 26-32
Citation
Gunawan, Burhan; Nugroho, Heri; Sibarani, Roy Panusuan. (2025). Dual GIP/GLP1-RA, GCGR/GLP-1 RA and GLP1-RA for the Treatment of Metabolic Dysfunction-associated Steatotic Liver Disease with Type 2 Diabetes: A Systematic Review and Meta-analysis.. TouchREVIEWS in endocrinology, 21(2), 26-32. https://doi.org/10.17925/EE.2025.21.2.5